NCT02999295 - A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

November 30, 2017

Study Completion Date

August 31, 2019

Conditions

Gastric CancerGastroesophageal Junction Region (GEJ) Cancer

Interventions

BIOLOGICAL

Ramucirumab

Ramucirumab (8 mg/kg) is administered.

BIOLOGICAL

Nivolumab

Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.

Trial Locations (1)

National Cancer Center Hospital, Tokyo